Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Do you know, that buy dildos is easy and safety?
Popular Articles

Public Meeting Of Somerset Primary Care Trust Board
The Board of Somerset Primary Care Trust will be holding its next Board meeting at 10.00 am on Wednesday 3rd June 2009 at Wynford House, Lufton Way, Lufton, Yeovil. Somerset. BA22 8HR.
drugs without prescription
Project To Develop HIV/AIDS Strategy For Libya Led By Liverpool School Of Tropical Medicine
Liverpool School of Tropical Medicine (LSTM) is leading a project to provide technical assistance to the Libyan government to finalise the development of a national HIV strategy and programme of support. The project is supported by a 1 million euro grant from the Delegation of the European Commission to Libya.
News of the day
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation For The Treatment Of Pancreatic Cancer
Epeius Biotechnologies announced that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs. The Fast Track Product designation, in particular, is granted following a critical evaluation of the "seriousness" or life-threatening nature of the unmet medical need, namely pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.
Endocrinology

ADVTX Announces New Treatment For Bleeding After Nuclear Exposure

Advanced Therapeutics & Co. (ADVTX) announced that Fibrinoplate-S™ has shown efficacy in reducing the bleeding in animals exposed to extreme doses of radiation. Survivors of a nuclear event or a dirty bomb explosion will have similar damage from the ionizing radiation of such bombs. "Acute radiation can severely damage the bone marrow," Richard Yen, Ph.D., M.D., CEO of ADVTX explained. "While existing medications can boost the production of red cells and white cells from the recovering bone marrow, there is no effective treatment for low concentrations of platelets except through platelet transfusion. Donor platelets, however, may not be available or adequately screened for pathogens during times of distress." Viable Alternative to Platelet Transfusion ADVTX Fibrinoplate-S, a suspension formulation of human albumin spheres coated with a coagulation factor (fibrinogen), mimics the action of activated platelets. Random clots have not been observed even as bleeding improves after the administration of Fibrinoplate-S. In preclinical trials, Fibrinoplate-S reduced bleeding within 2 hours after a bolus intravenous administration in test subjects with less than 1% of the normal platelet count. The beneficial effects last at least 24 hours. There is no need to match the recipients" blood types. Fibrinoplate-S can be given to a large number of patients quickly. Availability ADVTX can scale up its production of Fibrinoplate-S quickly. Government agencies may include Fibrinoplate-S in their emergency response plans by submitting a "pre-EUA" (pre-Emergency Use Approval) to the US FDA. Licensing outside the United States is available. Visit http://www.ADVTX.com. Advanced Therapeutics & Co.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009